A patient with intractable pain on high dose opioid therapy. Could we manage not to escalate the opioid dose? by Sobanski, Piotr et al.
www.advpm.eu36
Case report
Address to correspondence: Piotr Sobanski 
Hildegard Hospiz, St. Alban Ring 151. 4020 Basel, Switzerland  
e-mail: psoban@wp.pl
 Advances in Palliative Medicine 2012, 11, 36–40
 Copyright © 2012 Via Medica, ISSN 1898–3863
Piotr Sobanski1, Malgorzata Krajnik2 , Lucas Ritz1, Felix Schläfli3, Jan Kobialka1, Zbigniew Zylicz1
1Hildegard Hospiz, Basel, Switzerland  
2Chair of Palliative Care, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, Poland 
3Onco-Spitex, Spitex Basel, Basel, Switzerland
A patient with intractable pain  
on high dose opioid therapy.  
Could we manage not to  
escalate the opioid dose? 
Abstract
Prolonged opioid treatment reveals problems, like opioid tolerance and opioid induced hyperalgesia. On 
every stage of disease it should be remembered to use procedures that can have opioid dose sparing effect. 
We describe a patient with severe mixed neuropathic and nociceptive pain who despite complex medication 
embracing high dose of morphine suffered from untractable pain. He responded to opioid antagonist with 
sequential opioid rotation and a simple minimally invasive procedure.
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Introduction
Most of the cancer pain responds to simple 
pharmacological and non-pharmacological treat-
ments [1]. In the past, when the patient did not 
achieve satisfactory analgesia with opioid, its dose 
was sequentially increased with the conviction, that 
for the full agonists the relationship dose — effect 
is linear [2]. 
However, few patients never fitted into this para-
digm. Parallel to advancement in oncology, pa-
tients with cancer live longer and symptoms caused 
by disease and treatment become more complex. 
Therefore many patients are much longer exposed to 
painkillers. Prolonged opioid treatment reveals prob-
lems, which previously didn’t have chance to evolve, 
like opioid tolerance and opioid induced hyperal-
gesia (OIH). They are much more common nowa-
days than previously thought [3]. The awareness of 
different mechanisms responsible for diminished 
efficacy of analgesics and need of specific interven-
tions is crucial for effective symptom control. On 
every stage of disease it should be remembered to 
use procedures that can have opioid dose sparing 
effect. We describe a patient with severe mixed 
neuropathic and nociceptive pain who despite com-
plex medication embracing high dose of morphine 
suffered from untractable pain. He responded to 
opioid antagonist with sequential opioid rotation 
and a simple minimally invasive procedure.
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Case description
Fifty seven years old male with hormonally inac-
tive left adrenal gland cancer and multiple bone and 
liver metastases was admitted to Hildegard Hospiz 
due to intractable severe pain in spite of multimodal 
management. 
One year earlier after primary tumor excision the 
patient was treated with palliative chemotherapy 
(Carboplatin and VP16) and radiation therapy (46 Gy) 
to the area embracing tumour lodge, metastases in 
lumbar vertebrae L3 and in iliopsoas muscle. That 
improved pain control. Couple months later, due 
to progression of metastases the patient received 
sunitinib, and later doxorubicin with mitoxantrone. 
One year after diagnosis he started to complain of 
progressive pain in the right arm and right cervical 
area. Computed tomography revealed osteoblastic 
metastases in the humerus and in the spine on 
the level of C7, Th6, Th12 and suspected lesions in 
T9-T11with the compression of the spinal cord. He 
had been treated with localised radiotherapy to cervi-
cal area (20 Gy), but to no avail. Due to severe pain 
and poor general condition he was evaluated as be-
ing ineligible for any further diagnostic or therapeutic 
procedure and referred to hospice. On admission the 
patient complained of pain in the right arm and neck 
area with concomitant right arm paresis. The pain 
localisation and quality (burning, with mechanical 
allodynia) suggested brachial plexopathy. Another 
mixed neuropathic and nociceptive pain was lo-
calised in left lumbar area. It was described as dull 
ache aggravated by and resolved with sitting up in 
twined position to the left. According to its char-
acteristics, the pain was suspected to be caused by 
iliopsoas infiltration.
Pharmacological treatment of pain (localised 
in lumbar area at that time) had been started 
9 months earlier with transdermal (TD) fentanyl. 
Over time, stepwise dose escalation were needed 
to keep the pain under control. Four months before 
hospice admission patient experienced acute pain 
crisis (10/10 on the NRS) despite continuing previ-
ous medication. He was admitted to hospital and 
fentanyl, at that time 300 mcg/hour TD, was switched 
to morphine administrated as a continuous infusion 
via central venous port (CIVI). On discharge its dose 
in infusion was 600 mg/24 hour, with couple of 
rescue doses of 100 mg (total daily dose, calculated 
as oral dose, maximally 2400 mg/day). In subsequent 
weeks a new pain in right brachial and cervical 
regions, emerged. Many analgesics and co-analge-
sics had been introduced, but with no success. The 
10 days trial with oral corticosteroids was not effec-
tive either. Despite escalation of morphine dose the 
patient was still suffering severe pain, which was the 
direct indication for admission to hospice. The full 
treatment, immediately before hospice admission 
is given in Table 1. 
Due to severe pain in spite of increasing dos-
es of morphine, with a previous history of high 
dose fentanyl administration, the diagnosis of OIH 
and/or opioid tolerance was proposed. It was de-
cided to switch morphine into methadone and to 
start with a short term ultra low dose naloxone 
infusion. The significant improvement in pain con-
trol was achieved within two hours after naloxone 
0.002 mcg/kg/min = 0.18 mg/24 hours) infusion 
was started. After stable pain improvement was es-
tablished on naloxone, oral methadone was intro-
duced with intention of stepwise morphine replace-
ment. The patient was allowed to continue with 
morphine rescue doses as previously, but whilst on 
naloxone infusion, he hardly used them at all. At 
that moment the morphine dose to be swapped to 
methadone was equivalent to 3200 mg oral mor-
phine (= sume of Morphine Doses administrated 
as oral MST cont. and intravenous boluses). As OIH 
was suspected, oral methadone was started 10 mg 
as needed every 3 hours. The patient had been asked 
to use the IV morphine rescue doses (from CADD 
pump) as little, as possible. In the second day, the 
pain intensity decreased and naloxone was discon-
tinued. Then methadone dose was increased to 
20 mg as needed every 3 hours, while slowly reduc-
ing regular dose of morphine until discontinued on 
day 13th (Table 2). The methadone dose was titrated 
up to 480 mg per 24 hours (in 4 separated doses) 
which appeared to help well for the pain. Whilst on 
Table 1. Treatment on hospice entry
 Daily dose
Morphine HCl i.v. in CAD 672 mg  
 continuous infusion  
 + boluses 1000 mg






Lorazepam  1 mg
Pantoprazol 40 mg
Natrium picosulfat 5 mg
*The administered daily doses excide current recommendations
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methadone the patient started to complain of diar-
rhoea 15–30 minutes after administration of each 
dose. He tolerated methadone better when taking 
smaller every 3h doses. To lower methadone dos-
es and avoid gastrointestinal side effects, buprenor-
phine TD 17.5 mcg/h was added and uptitrated to 
70 mcg/h. As this appeared successful, methadone 
dose was stabilised at 360 mg and was changed back 
to a q8h regimen without gastrointestinal adverse ef-
fects. However, the patient was not completely pain 
free. Several painful spots were identified, and three 
most painfull of them were injected with bupivacaine 
and triamcinolon acetonide (15 mg and 40 mg, per 
point, respectively). This improved further the pain 
control, apparently not only in injected points but 
also pain in not injected spots . The patient went 
home, with a very good pain control. His medication 
at discharge is given in Table 3.
Parallel to methadone dose escalation stepwise 
prolongation of QT in ECG was observed (form 
410 ms to 470 ms). The patient remained symp-
tom free for 4 weeks. After that time his loss of 
energy hastened and general weakness started 
to progress more quickly than previously. Despite 
the lack of clear symptoms of acute suprarenal 
glands insufficiency, the probability of the deficit 
for glucocorticoids 4 weeks after triamcinolon 
administration was taken into account and pred-
nison 20 mg p.o. was prescribed. A few days later 
the patient started to complain of pain in the 
same areas as previously. The dose of methadone 
was increased by 50% which allowed to achieve 
satisfactory pain control. After several days the 
general condition worsened. In the last phase, when 
oral administration was no longer possible, metha-
done was administered IV. According to patients’ 
wishes he remained at home till the end. 
Discussion
Many factors might contribute to opioid dose 
escalation including cancer progression, new pain 
components, pharmacokinetical disturbances (f.ex. 
in opioid absorption or drug-drug interactions), 
psychological causes (anxiety, depression) and opioid 
tolerance or OIH. In case of the patient presented 
here none of those factors could be absolutely ex-
cluded. And this is not such rare situation especially 
in hospice environment where the details about 
tumour progression for obvious reasons were often 
difficult to obtain. However analysing history and the 
clinical picture we thought that the most important 
factor responsible for need to increase opioid is the 
OIH syndrome. Interventional techniques should 
have to be considered as they could effectively im-
prove pain control. However, their implementation 
would require further examinations (f.ex. MRI) and 
time. Whilst the pain intensity was so high and the 
prognosis so short term the effective pain control 
was urgently needed without any delay. 
There is a lack of studies investigating how often 
OIH is the cause of pain exacerbation among pa-
tients with advanced cancer. Its diagnosis in hospice 
patients is more difficult especially when OIH is seen 
as exacerbation of previous pain. Much more typical 
for OIH and easier to be recognised is appearance of 
Table 2. Opioids doses and pain intensity in switching period 
Day 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
MF (as  
oral dose) 4500 mg 3500 mg 1344  1344 +  1344 + 1344 + 1000 + 1000 + 1000 600 + 600 + 400 + 300+  200 + 0 +  0 +  
   1600 1300 1000 600 200 500 200 200 300  0 300  300 200 100
Methadone 0 50 90 120 150 220 290 230 390 430 500 490 360 360 360 360
Naloxone  0.18 0.18 mg/24 h
Bupreno- 
rphine TTS            17.5 35 35 35 70
Mean pain  
intensity (NRS) 10 10 Æ 2 2 4 4     5 6 4 3 2 2 1
Table 3. Medication on discharge 
Methadone 120 mg every 8 hours
Transtec TTS 70 mcg/h every 96 hours
Paracetamol 1.0 QDS
Pregabalin 300 mg TDS
Diclofenac SR 100 mg OD
Pantoprazol 40 mg OD
Mitrazepin 30 mg OD
Lorazepam 1 mg PRN
KCl retard drag. 8 mmol OD
Magnesium solution 5 mmol OD
Rescue medication:
Methadone p.o. 80 mg — PRN
Morphine hydrochloride 50 mg i.v. via central 
venous port — PRN
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diffuse allodynia (central sensitisation) not-associated 
with previous tissue damage [4, 5]. On the contrary 
several reports suggest that OIH embrace diminished 
pain threshold (hyperalgesia) but not allodynia [6]. 
In the simplest approach (but it is probably too 
simply) OIH should be suspected if not satisfactory 
controlled pain worsened after opioid dose escala-
tion [5]. In fact, more often in OIH morphine dose 
elevation improves pain only temporarily, making the 
dose escalation apparently helpful. The need for next 
dose escalations is usually misinterpreted as simple 
tolerance to opioids or disease progression and the 
idea to diagnose OIH is not taken into account. The 
exact molecular mechanisms of OIH remain still area 
of speculations and were discussed in this Journal 
previously (Table 4) [7]. 
The data about OIH in patients with cancer pain 
are scarce, but the problem seems to be more im-
portant than previously thought [3]. The broad 
introduction in daily practice of quantitative sensory 
testing could help to determine the OIH prevalence 
in cancer patients. Currently it is hypothesised that 
risk to develop OIH depends on dose and duration of 
opiod treatment and the drug used. However the fre-
quency how often  OIH seen, described depends on 
the test used to diagnose it [4].
There are two main arguments for diagnosis of 
OIH in our patient: 1/ rapid answer to ultra low 
dose of naloxone, and 2/ better efficacy of opioid 
with more anti-hyperalgesic activity (methadone) 
compared to morphine [5]. 
From two mostly often mentioned drugs to treat 
OIH (buprenorphine and methadone) we decided 
to use methadone, because of the morphine dose 
to be replaced was so high, that it was unrealistic 
to hope to reach this with buprenorphine patches. 
However the role of methadone in OIH treatment 
still remains the controversial [5]. 
In our patients morphine boluses where effective 
all the time, and, what is very interesting, their ef-
fectiveness increased after switching to methadone. 
We didn’t observe worsening of pain after morphine 
at any moment. 
However, the dose of methadone needed to 
control pain, comparable with previously used 
huge morphine dose, votes against pure OIH in 
described patient. Improvement of methadone 
effectiveness wasn’t observed after morphine dis-
continuation. It suggest that accumulation of 
morphine-3-glucoronides (M-3-G) was not respon-
sible for diminished opioid efficacy. NMDA receptor 
activation and M-3-G accumulation are supposed 
to play a role in patients treated with larger dos-
es of morphine [5, 8], what can’t be confirmed 
in our patient. Maybe additional mechanism of 
methadone as a NMDA antagonist could explain 
increased effectiveness of morphine given as res-
cue for breakthrough pain. On the very beginning 
of our treatment modification we observed clear 
improvement with ultra low dose naloxone infu-
sion. It suggests that the OIH in given patient can 
be explained with bizarre coupling of OR with G 
protein. During exposition of opioid receptors with 
opioids they become coupled with stimulating 
instead of inhibiting G protein. Replacement of 
Gi/O with Gs results in opposite intracellular signal 
transduction. In OIH opioids induce paradoxical 
cAMP elevation, instead of expected drop. Accord-
ing to this theory successful attempts to treat OIH 
with ultra-low dose of naloxone are described in 
the literature [9–11]. This intervention was suc-
cessful in given case. 
Buprenorphine might be more antihypergesic 
than other opioids due to its partial mu and 
ORL-1 agonistic activity as well as antagonistic 
effect against kappa and delta OR (on the other 
Table 4. Postulated mechanisms of OIH [4, 5, 11, 12]
Molecular level
1. Changes in opioid receptor conformation (switching coupling with Go/i to Gs)
2. Stimulation of calcium/calmodulin-dependent protein kinase II (CaMKIIalfa)
3. Stimulation of opioid receptor-like receptors (ORL-1)
Neuroanatomical level
1. Sensitisation of peripheral nerve endings 
2. NMDA mediated (reflex increase in downstream stimulation of NMDA receptors which facilitate nociceptive 
stimulus transmission)
3. Spinal dynorphine transmission
4. Enhanced production, release or diminished reuptake of nociceptive neurotransmitters
5. Sensitisation of second order neurons to nociceptive neurotransmitters
6. Activation of toll-like receptor 4 (TLR4) expressed by glia 
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hand, kappa receptor stimulation for example 
with dynorphin can evok OIH) [12]. These complex 
activities against different OR types are combined 
with interaction with different G protein (Gs and 
Go/i). One of growing hypothesis about mechanism 
of OIH is switching opioid receptor coupling with 
another type of G protein. 
What could be done better? Considering 
1.non-pharmacological methods of analgesia, 
however very difficult in the patient situation; 2. 
stronger NMDA antagonist, such as ketamine; 3. 
longer infusion of ultra low dose of naloxone; 4. 
earlier introduction of steroids — we believe that 
that beneficial effect on different pains (not only 
local) of depo steroids was partially dependent on 
the systemic action due to significant total dose of 
injected corticosteroids; 
However, most of the time the level of analgesia 
was reasonable and we had impression that the 
patient did not suffer due to pain. 
Conclusion
This patient was an example of severe and com-
plex pain of mixed nociceptive and neuropathic 
origin. Simple treatment with opioids and adju-
vants was not successful and the patient developed 
severe OIH. Ultra low dose of naloxone, swap of 
morphine to methadone and buprenorphine as well 
as the specific treatment of the pain due to peripheral 
nerve compression appeared to be successful and al-
lowed patient to be discharged and to die at home. 
The key to the diagnosis and treatment of this patient 
was taking minute history of pain symptoms as well 
as attention to details.
Piśmiennictwo
1. Portenoy R.K. Treatment of cancer pain. Lancet 2011; 
377: 2236–2247.
2. Cady J. Understanding opioid tolerance in cancer pain. 
Oncol. Nurs Forum 2001; 28: 1561–1568 (quiz 1569–
1570).
3. Zylicz Z., Twycross R. Opioid-induced hyperalgesia may 
be more frequent than previously thought. J. Clin. Oncol. 
2008; 26: 1564 (author reply: 1565).
4. Tompkins D.A., Campbell C.M. Opioid-induced hy-
peralgesia: clinically relevant or extraneous research 
phenomenon? Curr. Pain Headache Rep. 2011; 15: 
129–136.
5. Lee M., Silverman S.M., Hansen H., Patel V.B., Manchikanti 
L. A comprehensive review of opioid-induced hyperalge-
sia. Pain Physician 2011; 14: 145–161.
6. Chu L.F., Clark D.J., Angst M.S. Opioid tolerance and 
hyperalgesia in chronic pain patients after one month of 
oral morphine therapy: a preliminary prospective study. 
J. Pain 2006; 7: 43–48.
7. Kenter E.G.H., Zylicz Z. Differentiating neuropathic pain, 
opioid-induced hyperalgesia and opioid tolerance; con-
siderations following a remarkable case. Adv. Pall. Med. 
2010; 9: 93–98.
8. Chu L.F., Angst M.S., Clark D. Opioid-induced hyperalgesia 
in humans: molecular mechanisms and clinical considera-
tions. Clin. J. Pain. 2008; 24: 479–496.
9. Darnell C.M., Thompson J., Stromberg D., Roy L., Sheeran 
P. Effect of low-dose naloxone infusion on fentanyl re-
quirements in critically ill children. Pediatrics 2008; 121: 
e1363–e1371.
10. Wang H.Y., Friedman E., Olmstead M.C., Burns L.H. 
Ultra-low-dose naloxone suppresses opioid tolerance, 
dependence and associated changes in mu opioid re-
ceptor-G protein coupling and Gbetagamma signaling. 
Neuroscience 2005; 135: 247–261.
11. Wang H.Y., Burns L.H. Naloxone’s pentapeptide binding 
site on filamin A blocks Mu opioid receptor-Gs coupling 
and CREB activation of acute morphine. PLoS One 2009; 
4: e4282.
12. Induru R.R., Davis M.P. Buprenorphine for neuropathic 
pain-targeting hyperalgesia. Am. J. Hosp. Palliat. Care 
2009; 26: 470–473.
